Boehringer Ingelheim and Gubra begin Phase I trial of drug candidate for obesity

Boehringer Ingelheim and Gubra begin Phase I trial of drug candidate for obesity

Source: 
Clinical Trials Arena
snippet: 

Boehringer Ingelheim and Gubra have initiated a Phase I clinical trial of BI 3034701, a long-acting triple agonist peptide designed to treat obesity.

The randomised, first-in-human, placebo-controlled trial will evaluate the drug’s tolerability, safety, and pharmacokinetics and be carried out in two parts.